Molecule intelOpportunity: Lower0

Olmesartan Medoxomil

50 brands · 18 companies · product forms

Opportunity snapshot

Launch attractiveness
33
Market saturation
52
Price room
100
Regulatory risk
0
50
brands
18
companies
Rs 403.8
median price
49
price points
26.54x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 10%

Price room

Across observed sources and strengths
CheapestRs 169.6
MedianRs 403.8
Most expensiveRs 4,501.6
Spread26.54×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 26.54x across 49 trusted points (Rs 169.6-4501.6). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Olmesartan Medoxomil — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(100) + 20% low-competition(48) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

18 canonical companies and 50 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 26.54x across 49 trusted points (Rs 169.6-4501.6). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Reduced by: no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.